Kappa Opioids and the Modulation of Pain

Overview

Journal Psychopharmacology (Berl)

Specialty Pharmacology

Date 2010 Apr 8

PMID 20372880

Citations 55

Authors

Bronwyn Kivell

Thomas E Prisinzano

Affiliations

Soon will be listed here.

Abstract

Background And Rationale: Pain is a complex sensory experience, involving cognitive factors, environment (setting, society, and culture), experience, and gender and is modulated significantly by the central nervous system (CNS). The mechanisms by which opioid analgesics work are understood, but this class of drugs is not ideal as either an analgesic or anti-hyperalgesic. Accordingly, considerable effort continues to be directed at improved understanding of nociceptor function and development of selective analgesics that do not have the unwanted effects associated with opioid analgesics.

Objective: The purpose of this paper is to provide a review of the role of KOP receptors in the modulation of pain and highlight several chemotypes currently being explored as peripherally restricted KOP ligands.

Results: A growing body of literature has shown that KOP receptors are implicated in a variety of behavioral pain models. Several different classes of peripherally restricted peptidic and nonpeptidic KOP agonists have been identified and show utility in treating painful conditions.

Conclusion: The pharmacological profile of KOP agonists in visceral pain models suggest that peripherally restricted KOP agonists are potentially useful for a variety of peripheral pain states. Further, clinical investigation of peripherally restricted KOP agonists will help to clarify the painful conditions where KOP agonists will be most effective.

Citing Articles

Opioid receptor signaling throughout ontogeny: Shaping neural and behavioral trajectories.

Spodnick M, McElderry S, Diaz M Neurosci Biobehav Rev. 2025; 170:106033.

PMID: 39894419 PMC: 11851333. DOI: 10.1016/j.neubiorev.2025.106033.

Oxycodone for analgesia in children undergoing endoscopic retrograde cholangiopancreatography: a randomized, double-blind, parallel study.

Ji W, Sun L, Huang Y, Bai J, Zheng J, Zhang K Front Pharmacol. 2025; 15():1515501.

PMID: 39845794 PMC: 11751031. DOI: 10.3389/fphar.2024.1515501.

Impact of renal impairment on the pharmacokinetic profile of intravenous difelikefalin, a kappa opioid receptor agonist for the treatment of pruritus.

Spencer R, Noonan P, Marbury T, Menzaghi F BMC Nephrol. 2024; 25(1):351.

PMID: 39402448 PMC: 11476771. DOI: 10.1186/s12882-024-03790-w.

Synthesis and evaluation of 3,4,5-trisubstituted triazoles as G protein-biased kappa opioid receptor agonists.

Trojniak A, Dang V, Czekner K, Russo R, Mather L, Stahl E Eur J Med Chem. 2024; 276:116627.

PMID: 38971050 PMC: 11316643. DOI: 10.1016/j.ejmech.2024.116627.

Quantification of observable behaviors following oral administration of oxycodone and nalfurafine in male rhesus monkeys.

Huskinson S, Platt D, Smith Z, Doyle W, Zamarripa C, Dunaway K Drug Alcohol Depend. 2023; 252:110953.

PMID: 37734282 PMC: 10615792. DOI: 10.1016/j.drugalcdep.2023.110953.

References

Vanderah T . Delta and kappa opioid receptors as suitable drug targets for pain. Clin J Pain. 2009; 26 Suppl 10:S10-5. DOI: 10.1097/AJP.0b013e3181c49e3a. View

Stein C, Millan M, Shippenberg T, Peter K, Herz A . Peripheral opioid receptors mediating antinociception in inflammation. Evidence for involvement of mu, delta and kappa receptors. J Pharmacol Exp Ther. 1989; 248(3):1269-75. View

Stein C . Peripheral mechanisms of opioid analgesia. Anesth Analg. 1993; 76(1):182-91. DOI: 10.1213/00000539-199301000-00031. View

Shannon H, Eberle E, Mitch C, McKinzie D, Statnick M . Effects of kappa opioid receptor agonists on attention as assessed by a 5-choice serial reaction time task in rats. Neuropharmacology. 2007; 53(8):930-41. DOI: 10.1016/j.neuropharm.2007.09.002. View

Walker J . Anti-inflammatory effects of opioids. Adv Exp Med Biol. 2003; 521:148-60. View

Kim S, Chung J . An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain. 1992; 50(3):355-363. DOI: 10.1016/0304-3959(92)90041-9. View

Delgado-Aros S, Chial H, Camilleri M, Szarka L, Weber F, Jacob J . Effects of a kappa-opioid agonist, asimadoline, on satiation and GI motor and sensory functions in humans. Am J Physiol Gastrointest Liver Physiol. 2003; 284(4):G558-66. DOI: 10.1152/ajpgi.00360.2002. View

Millan M . Kappa-opioid receptors and analgesia. Trends Pharmacol Sci. 1990; 11(2):70-6. DOI: 10.1016/0165-6147(90)90321-x. View

Teksin Z, Lee I, Nemieboka N, Othman A, Upreti V, Hassan H . Evaluation of the transport, in vitro metabolism and pharmacokinetics of Salvinorin A, a potent hallucinogen. Eur J Pharm Biopharm. 2009; 72(2):471-7. PMC: 2719774. DOI: 10.1016/j.ejpb.2009.01.002. View

10.

Millan M, Czlonkowski A, Morris B, Stein C, Arendt R, Huber A . Inflammation of the hind limb as a model of unilateral, localized pain: influence on multiple opioid systems in the spinal cord of the rat. Pain. 1988; 35(3):299-312. DOI: 10.1016/0304-3959(88)90140-6. View

11.

Spanagel R, Herz A, Shippenberg T . Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway. Proc Natl Acad Sci U S A. 1992; 89(6):2046-50. PMC: 48593. DOI: 10.1073/pnas.89.6.2046. View

12.

Riviere P . Peripheral kappa-opioid agonists for visceral pain. Br J Pharmacol. 2004; 141(8):1331-4. PMC: 1574907. DOI: 10.1038/sj.bjp.0705763. View

13.

Chu G, Gu M, Cassel J, Belanger S, Graczyk T, DeHaven R . Potent and highly selective kappa opioid receptor agonists incorporating chroman- and 2,3-dihydrobenzofuran-based constraints. Bioorg Med Chem Lett. 2005; 15(23):5114-9. DOI: 10.1016/j.bmcl.2005.08.094. View

14.

Horan P, Porreca F . Lack of cross-tolerance between U69,593 and bremazocine suggests kappa-opioid receptor multiplicity in mice. Eur J Pharmacol. 1993; 239(1-3):93-8. DOI: 10.1016/0014-2999(93)90980-v. View

15.

Danzebrink R, Green S, Gebhart G . Spinal mu and delta, but not kappa, opioid-receptor agonists attenuate responses to noxious colorectal distension in the rat. Pain. 1995; 63(1):39-47. DOI: 10.1016/0304-3959(94)00275-J. View

16.

Wang Z, Gardell L, Ossipov M, Vanderah T, Brennan M, Hochgeschwender U . Pronociceptive actions of dynorphin maintain chronic neuropathic pain. J Neurosci. 2001; 21(5):1779-86. PMC: 6762963. View

17.

LE Bars D, Gozariu M, Cadden S . Animal models of nociception. Pharmacol Rev. 2001; 53(4):597-652. View

18.

Freye E, Hartung E, Schenk G . Bremazocine: an opiate that induces sedation and analgesia without respiratory depression. Anesth Analg. 1983; 62(5):483-8. View

19.

BURTON M, Gebhart G . Effects of kappa-opioid receptor agonists on responses to colorectal distension in rats with and without acute colonic inflammation. J Pharmacol Exp Ther. 1998; 285(2):707-15. View

20.

Prisinzano T, Rothman R . Salvinorin A analogs as probes in opioid pharmacology. Chem Rev. 2008; 108(5):1732-43. PMC: 2648615. DOI: 10.1021/cr0782269. View